During the past decade, Rey y Oreilly Limitada ( Site 1048) conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 1 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Rey y Oreilly Limitada ( Site 1048)" are "Prostatic Neoplasms" (3 trials). Many other conditions were trialed in "Rey y Oreilly Limitada ( Site 1048)" in a lesser frequency.

Most popular intervention types in "Rey y Oreilly Limitada ( Site 1048)" are "Biological" (3 trials) and "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (3 trials), "Enzalutamide" (2 trials), "Placebo" (2 trials), "Prednisone" (2 trials) and "Abiraterone acetate" (1 trials). Other intervention names were less common.

The vast majority of trials in "Rey y Oreilly Limitada ( Site 1048)" are 3 trials for "Male" genders.

Currently, there are NaN active trials in "Rey y Oreilly Limitada ( Site 1048)". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Rey y Oreilly Limitada ( Site 1048), undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Rey y Oreilly Limitada ( Site 1048), 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".